BOOT CAMP

May 4–5, 2023

New York Bar Association, New York, NY

Intensive training in the essentials and complexities of pricing calculations, rebates, and reporting under the Medicaid, Medicare, and PHS 340B Programs

A leading faculty of experienced practitioners will help you master core drug pricing concepts and calculations, and help you:

Angle-Right DECIPHER the complexities of the Inflation Reduction Act

Angle-Right UNDERSTAND how price is established and how the rebate system works

Angle-Right BUILD a live glossary of Medicaid and Medicare terminology

Angle-Right COMPREHEND the mechanics of Medicare Part B and D

Angle-Right DEVELOP a thorough understanding of different pricing benchmarks and calculations including AWP, AMP, BP and much more

Angle-Right UNDERSTAND the nuances of pricing and reimbursement under the Public Health Service 340B Program

Angle-Right DETERMINE appropriate coding, coverage, and reimbursement for new products

Distinguished Co-Chair: Trevor Wear Partner Sidley Austin LLP

Exclusive Fireside Chat: James Stansel Executive Vice President and General Counsel PhRMA

ATTEND the Pre-Conference and Post-Conference Workshops to enhance your understanding of key concepts and the latest trends in biopharmaceutical pricing and rebates:

MAY 3, 2023

WORKSHOP A Government Payor Program

101: Primer on the Pricing Essentials of the Medicare, Medicaid, and PHS 340B Program

WORKSHOP B Inflation Reduction Act

Boot Camp: An In-Depth Review of Changes to Medicare Pricing under the IRA

MAY 5, 2023

WORKSHOP C Understanding the Big Picture: Connecting the Dots Between Government Payor Programs

Get Your All Access Pass to Include All Workshops!

Withboth federal and state law makers engaging in greater scrutiny of prescription drug pricing, now is the time when industry professionals must stay up to date on the latest amendments to government payor programs as well as their impact on the private sector. Join us to gain a holistic view of how these government payor programs relate and often intersect with each other.

Who Will You Meet?

PHARMACEUTICAL COMPANIES

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pricing, Pricing Strategy, Pricing Analytics

- Contracts and Reimbursement

- Managed Care

- Government Programs

- Medicaid/Medicare Rebates

- Finance/Accounting/Audit

- Government Affairs

The Inflation Reduction Act of 2022 Shifted the World

of Government Payor Programs and Raises a Host of Anticipated Questions for Rx Drug Pricing and Rebates

The implementation of IRA which began earlier this year and has significantly impacted Medicare, while posing indirect affects to the other government payor programs. Attend this event and understand the new provisions under the IRA. Explore and learn about the drug pricing negotiation program, dynamic changes Medicare Part D standard discounts, Part B reimbursements for biosimilars, and related new concerns with the Anti-Kickback statute.

Understand the Essentials to Pricing, Negotiations, and Rebates under Medicare Part B and D

Medicare has evolved significantly, leaving many professionals questioning the process of pricing, negotiations, and rebates within this realm. We will examine how to negotiate maximum fair price under Part B and D, streamline inflation rebate penalties under Part B and D as well as explore the provisions of the Drug Wastage Rule.

Explore New Developments and Impacts of the PHS 340B Program

Recent updates to the 340B program have added to the urgency of pricing and coverage will look. Join us as we take a deep dive into this evolving government payor program as leading professionals discuss how to calculate pricing under 340B, while defining and redefining 340B entities and who qualifies. We will provide an in-depth look into the new 340B ADR rule and will help you form strategies to address the limiting scope of the ADR timeline process.

Obtain a Thorough Understanding of All Complexities Under Medicaid Drug Pricing and Rebates

The provisions and analysis under Medicaid can often lead to confusion and improper calculations that pose severe consequences on professionals and companies involved. We will examine the formulas and correct calculations needed for drug pricing and rebates, while highlighting the difference between brand drugs versus generic drugs. While adding to your living glossary list of Medicaid terminology, learn about the indirect impacts the IRA has on Medicaid.

Register today for the most comprehensive “how to” Rx Drug Pricing conference, where top minds convene to network and engage in thought-provoking discussions as well as provide practical advice for engaging in the pricing and rebate process.

- Marketing

• Compliance Officers

LAW FIRMS

• Attorneys with practice areas in:

- Pharmaceuticals

- Healthcare

- Food and Drug

PBMS

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Contract Management

- Network Pharmacy

- Retail Pharmacy Operations

- Government Programs

- Pricing and Operations

- Clinical Operations

- Industry Relations/Government Affairs

• Financial Analysts

PHARMACIES

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pricing

- Business Development

PLANS

• Corporate Counsel/General Counsel

• Vice Presidents, Officers, Directors and Managers for:

- Pharmacy Networks

- Pharmaceutical Contracting

- Clinical

- Pharmacy Services